businessfortnight

Sydney:  Asian stocks, closing in on their worst year since 2011, got some relief on the last day of 2018 after U.S. President Donald Trump reported “big progress” in trade talks with his Chinese counterpart. The yen declined. Equities gained in Hong Kong and Australia, along with S&P 500 Index futures, after Trump said in a tweet that negotiations were “moving along very well” toward a comprehensive deal and Chinese state media cited President Xi Jinping as saying he believed both sides wanted “stable progress.” Trading will be thin with major markets in Japan and China closed and shortened sessions elsewhere. Oil extended gains on the trade optimism. Asian stocks rise over hopes of easing Us-China trade war The positive sentiment was damped a bit after a gauge of China’s manufacturing industry missed estimates to decline in December, underscoring concern over the slowing domestic economy. The manufacturing purchasing managers index fell to 49.4, falling below 50 — the line betwe

New York:  Asian stocks climbed on Thursday after the biggest rally in U.S. equities since 2009 offered relief from this month’s wrenching global market downturn. Japanese benchmarks jumped about 4 percent at the open and Australian shares advanced more than 1 percent as trading resumed after holidays there. Korean stocks were flat, however, and U.S. futures dipped, suggesting the follow-through from the blow-out session on Wall Street — where key indexes climbed about 5 percent or more — has limits. Crude oil prices built on gains of more than 8 percent overnight. Ten-year Treasury yields are holding around 2.80 percent. Some 99 percent of S&P 500 members finished in the green, the Dow Jones Industrial Average jumped more than 1,050 points for its biggest-ever point gain. Asia stocks jump on biggest US rally since 2009 “We’re going to have a lot of volatility. But this base case of ‘the world is coming to an end,’ just given the fundamental data out there, doesn’t make any sense.

Zydus Cadila has received final approval from the US health regulator to market Doxycycline Hyclate delayed-release tablets, used to treat bacterial infections. Zydus Cadila gets USFDA nod for 2 drugs Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market the drug in the strengths of 75 mg, 100 mg and 150 mg, the company said in a BSE filing. Zydus Cadila said the drug will be produced at the group’s formulations manufacturing facility at SEZ, Ahmedabad. The group has also received tentative approval for Febuxostat tablets in the strengths of 40 mg and 80 mg, used to treat hyperuricemia (constantly high levels of uric acid) in adults who have gout. The group has more than 241 approvals, and so far filed over 340 abbreviated new drug applications (ANDAs) since it started filings in 2003-04. Shares of Cadila Healthcare, the listed entity of the group, were trading 0.13 per cent lower at Rs 341.60 per scrip on BSE. source: money

17 th  Dec 2018:  Bajaj Auto, one of India’s leading automobile companies, has launched the new Platina 110 to provide customers with a new standard in ride comfort. The new Platina 110 couples breakthrough comfort, with higher torque than any bike in its class for an effortless ride, even on inclines. In addition to superior comfort and performance, this stylish bike has additional safety as well. Bajaj Auto launches the new Platina 110 The new Platina 110 is the first bike in its class to come with Anti-Skid Braking System as standard. Anti-Skid braking delivers an even brake force on both wheels for safer riding at all riding conditions and speeds. The Platina 100 ES is already acknowledged to be the most comfortable bike in its class with 20% lesser jerks.  The new Platina 110 is even more comfortable: It is equipped with a first-in-class Spring-on-Spring suspension with Nitrox Gas charged shock absorbers to absorb jerks from all types of roads. It offers a stress free journey bot

The government is planning to introduce amendments to the Drugs and Cosmetics Act, 1940 which will provide compensation to patients if they are sold a faulty medical device by a manufacturer or importer. The decision has been taken in the backdrop of the uproar caused earlier this year in India and abroad over defective hip implants from US-based Johnson & Johnson. Govt plans new rule to get patients compensation for defective medical devices The proposal to reimburse people affected by faulty medical devices will be taken up at the Drug Technical Advisory Board (DTAB), scheduled a week from today, Business Standard reported while quoting sources. If the proposed amendments get the green flag from DTAB, they will be tabled before the health ministry for approval. While in a nascent stage, a decision could be taken on the proposal by the end of this fiscal, the report added. While some stakeholders believe amending the Drugs and Cosmetics Act to include compensations is a quick and